Mirati - oncology?

Quote






anonymous said:
Lots of rejects. They want the cash. Zero-knowledge to offer for Lung. Once they get that first appointment they will be talking about it for years. Because they won't get a second appointment due to the fact they are rejects. Let's see how the tale of the tape plays out...
Click to expand...

This thing is dead before it even gets out of the gate.
 






It will be like Puma, Clovis ect. half your stock depends on the strike price - so that becomes underwater once the drug is dominated by lumarkras. Mirati is bloated and is worth less than half (approx. 2.5 billion tops) (Price is roughly 40-50 bucks a share).. The other half of your stock is vested at 25% in 4 years. So you will make roughly 25k next year at this time. So enjoy that for the pain ahead.

Your high base...once your try to get a real job you are overpaid and untouchable. Dear, Mr. Employer I wat to come home to XYZ company but I make 200k base. No one will welcome you back. Welcome to your new life. A bonafide REJECT.

Get your mind right!
 






anonymous said:
It will be like Puma, Clovis ect. half your stock depends on the strike price - so that becomes underwater once the drug is dominated by lumarkras. Mirati is bloated and is worth less than half (approx. 2.5 billion tops) (Price is roughly 40-50 bucks a share).. The other half of your stock is vested at 25% in 4 years. So you will make roughly 25k next year at this time. So enjoy that for the pain ahead.

Your high base...once your try to get a real job you are overpaid and untouchable. Dear, Mr. Employer I wat to come home to XYZ company but I make 200k base. No one will welcome you back. Welcome to your new life. A bonafide REJECT.

Get your mind right!
Click to expand...


You put in a lot of time and effort into bashing others. Just enjoy your fantastic decision making and career managment!
 
























anonymous said:
Companies are bought before a sales build out based on promising data. Statistically, this will lose half its value by year-end. Buyer Beware.
Click to expand...

Which isn’t happening at the rate it once did. The bigs are willing to pay a premium for a real revenue stream, gone are the days of multiples pre commercialization. If anyone thought this was a good drug it would have been scooped up…now you better drive a big rev number or else this is Clovis and Tesaro part two.
 






hearing lots of people are leaving medical affairs or are about to after they delayed bonuses to stem the tide. Other than her sycophants, absolutely everyone hates the head of medical affairs apparently due to very poor strategy and micro-management culture. She does not listen or take advice at all - the leadership are gutless and have surrounded themselves with shills all playing the game. Glad I never joined now.
 






Yes! smart analysis, they must prove a strong uptick/revenue stream. Look at TG Therapeutics (TGTX). I hate to see this company sink as it has such promise. If the team was built strategically it could compete against Amgen. Linkedin new hires demonstrate the talent pool. Lift-off is delayed due to pisspoor work ethic/people.
 


















anonymous said:
hearing lots of people are leaving medical affairs or are about to after they delayed bonuses to stem the tide. Other than her sycophants, absolutely everyone hates the head of medical affairs apparently due to very poor strategy and micro-management culture. She does not listen or take advice at all - the leadership are gutless and have surrounded themselves with shills all playing the game. Glad I never joined now.
Click to expand...

Can someone shed more light on these posts regarding medical team? I'm applying to some of the positions, and want to make sure I know what I am getting myself into before its too late to pull out of the process!!!!
 












They are trying to build up the half-life story and the 18 horse pills to take BID. that's 36 pills total (gigantic walnut-sized poppers, 33% bigger than PUMA nutz)) The leadership team believes that Lumakras once-daily dosing is not as good. Remember these are PUMA managers... PUMA(now 2 buck f*&).
So regarding medical- there is a push on this dosing regimen. The commercial side can open mouths wide and chomp this. However, if you are smart, which you might be, then you do the math...
 






























The directors and managers are weak. Yes, they have put their tip and nip in oncology. However, the tip and nip haven't sold in lung. They hired PUMA rejects to look good. It is across the board. stock bloated like the managers ego
 






Top Bottom
Back
Quote